News & Perspective

Nov 09, 2012

Nov 09, 2012

BioCryst may drop quest for US approval of peramivir

(CIDRAP News) – BioCryst Pharmaceuticals Inc. signaled yesterday it will probably give up on seeking a US license for the influenza drug peramivir, a move that would reduce the already limited options for severely ill flu patients in need of an intravenous antiviral drug.

Mar 23, 2018

Mar 23, 2018

ASP Scan (Weekly) for Mar 23, 2018

Contact precautions and resistance
Antimicrobial use on farms
CARB-X funds antibiotic candidate
Resistance surveillance in poor nations
MDR-TB treatment outcomes
New stewardship e-book
Sepsis, diagnostics technology
Resistant TB in Europe
Appropriate C diff testing
Fast sepsis detection

Jun 11, 2021

Jun 11, 2021

ASP Scan (Weekly) for Jun 11, 2021

WHO stewardship documents
Reduced antibiotic use in UK pigs
FDA animal antibiotics guidance
Funding for rapid susceptibility test
CARB-X funds for sepsis diagnostic
Japanese funding for new antibiotics
Rapid ILI tests and antibiotic Rx

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Unorthodox Philanthropy logo and text 'Leading Underwriter'3M logoGilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»